CRBP - Company ID 0001595097
The table below shows Corbus Pharmaceuticals Holdings, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0.00 | $881.71K | $3.94M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $70.09M | $32.22M | $31.17M | $16.14M | $36.45M | $98.27M |
| SG&A |
Corbus Pharmaceuticals Holdings, Inc. reported annual revenue of $0.00 for fiscal year 2022. That is down 100.0% from $881.71K in fiscal 2021. Over the 8 fiscal years shown, annual revenue declined from $648.38K (FY 2015) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.21M |
| $16.50M |
| $13.91M |
| $18.70M |
| $20.43M |
| $28.48M |
| Operating income | -$85.31M | -$48.72M | -$45.08M | -$39.84M | -$55.99M | -$122.81M |
| Income tax | $0.00 | $0.00 | - | - | - | - |
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -$45.64M | -$111.27M |
| EPS (diluted) | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | - |